

## **Germany Rna Interference (Rnai) Drug Delivery Market Forecast 2024-2032**

Market Report | 2024-06-17 | 138 pages | Inkwood Research

### **AVAILABLE LICENSES:**

- Single User Price \$1100.00
- Global Site License \$1500.00

### **Report description:**

#### **KEY FINDINGS**

The Germany RNA interference (RNAi) drug delivery market is approximated to grow at a CAGR of 22.94% over the forecast period of 2024-2032. It is set to reach a revenue of \$23164.24 million by 2032.

#### **MARKET INSIGHTS**

The Germany RNA interference (RNAi) drug delivery market is experiencing significant growth, driven by the increasing demand for RNAi therapeutics. This surge in demand is fueled by the promising potential of RNAi technologies in treating various diseases, offering a novel approach that targets the root cause at the genetic level. As research and development in RNA-based therapies continue to advance, the market is expected to see substantial growth. This growth reflects the broader global trend towards personalized and precision medicine.

In Germany, the rising prevalence of chronic diseases is further boosting the demand for RNAi drug delivery solutions. Conditions such as cancer, cardiovascular diseases, and neurological disorders are becoming more common, necessitating innovative treatment approaches. RNAi therapeutics offer a promising solution by effectively silencing specific genes involved in disease progression. This targeted approach enhances the efficacy of treatments and minimizes side effects, making it a preferable option in the management of chronic diseases.

Among the various applications of RNAi drug delivery, cardiology stands out as the fastest-growing segment. The application of RNAi in cardiology focuses on addressing genetic factors contributing to heart diseases, offering new hope for patients with conditions that are difficult to treat with conventional therapies. The ability of RNAi to precisely target and regulate specific genes involved in cardiovascular diseases makes it a transformative approach. This capability drives its rapid adoption and growth within this medical field.

Nanoparticle drug delivery technology is predominantly preferred for RNAi therapeutics due to its efficiency in delivering RNA molecules to target cells. Nanoparticles protect RNA molecules from degradation and enhance their delivery to the desired site of action within the body. This technology ensures that the therapeutic RNA reaches its target efficiently, improving the overall effectiveness of the treatment. The adoption of nanoparticle drug delivery systems is a major factor propelling the growth of the market in Germany. This aligns with the increasing emphasis on precision and efficacy in modern medical treatments.

#### **SEGMENTATION ANALYSIS**

The Germany RNA interference (RNAi) drug delivery market segmentation incorporates the market by application and technology. The application segment is further bifurcated into oncology, infectious disease, neurology, cardiology, metabolic disorders,

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

ophthalmology, urology, and other applications. Oncology is a prominent sub-segment within the market in Germany. RNAi therapeutics have shown considerable promise in targeting and silencing specific genes responsible for cancer progression. By inhibiting these genes, RNAi can effectively reduce tumor growth and enhance the efficacy of existing treatments. This approach offers new avenues for cancer treatment and holds the potential to overcome resistance to conventional therapies. As a result, it has become a critical area of focus in the ongoing fight against cancer.

Neurology is another key sub-segment where RNAi technologies are making significant strides. Neurological disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, often involve complex genetic components that are difficult to treat with traditional methods. RNAi offers a novel approach by targeting these genetic factors directly, potentially altering the course of these debilitating conditions. The ability to precisely regulate gene expression in the nervous system opens up new possibilities for managing and treating neurological diseases, driving the growth of RNAi applications in this field.

Ophthalmology also benefits from RNAi drug delivery systems, particularly in the treatment of diseases like macular degeneration and glaucoma. These conditions often result from genetic mutations or abnormal gene expressions that can be effectively targeted by RNAi therapeutics. By silencing the problematic genes, RNAi can help preserve vision and improve the quality of life for patients suffering from these eye diseases. The precision and specificity of RNAi make it an attractive option for ophthalmological applications, further expanding its market potential.

#### COMPETITIVE ANALYSIS

Top players operating in the Germany RNA interference (RNAi) drug delivery market include Alnylam Pharmaceuticals Inc, Arbutus Biopharma Corp, Ionis Pharmaceuticals Inc, etc.

Alnylam Pharmaceuticals Inc, headquartered in the United States, is a global biopharmaceutical company specializing in RNAi-based therapeutics. With five approved RNAi drugs, Alnylam targets genetically validated genes linked to human diseases. The company's strategy focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. Utilizing N-acetylgalactosamine (GalNAc) conjugates and lipid nanoparticles (LNP) for drug delivery, Alnylam effectively administers treatments, including the use of hexadecyl (C16) for ocular and CNS delivery.

#### Table of Contents:

##### TABLE OF CONTENTS

##### 1. RESEARCH SCOPE & METHODOLOGY

###### 1.1. STUDY OBJECTIVES

###### 1.2. METHODOLOGY

###### 1.3. ASSUMPTIONS & LIMITATIONS

##### 2. EXECUTIVE SUMMARY

###### 2.1. MARKET SIZE & ESTIMATES

###### 2.2. COUNTRY SNAPSHOT

###### 2.3. COUNTRY ANALYSIS

###### 2.4. SCOPE OF STUDY

###### 2.5. CRISIS SCENARIO ANALYSIS

###### 2.6. MAJOR MARKET FINDINGS

###### 2.6.1. CARDIOLOGY IS THE FASTEST-GROWING RNAI DRUG DELIVERY APPLICATION

###### 2.6.2. NANOPARTICLE DRUG DELIVERY IS THE MAJORLY PREFERRED RNAI DRUG DELIVERY TECHNOLOGY

##### 3. MARKET DYNAMICS

###### 3.1. KEY DRIVERS

###### 3.1.1. INCREASING DEMAND FOR RNA-BASED THERAPEUTICS TO STIMULATE MARKET GROWTH

###### 3.1.2. RISING PREVALENCE OF CHRONIC DISEASES FOSTERS MARKET DEMAND

###### 3.1.3. GROWING INVESTMENT IN RNA-BASED RESEARCH TO ESCALATE THE MARKET GROWTH

###### 3.2. KEY RESTRAINTS

###### 3.2.1. THE COMPLEXITY OF RNAI TECHNOLOGY IS PREDICTED TO HINDER MARKET DEMAND

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

3.2.2. REGULATORY CHALLENGES ARE EXPECTED TO FURTHER COMPLICATE MARKET GROWTH

#### 4. KEY ANALYTICS

##### 4.1. KEY MARKET TRENDS

4.1.1. RNAI DRUGS HAVE APPLICATIONS IN CANCER TREATMENT

4.1.2. INFECTIOUS DISEASES ARE LEADING TO INCREASED TRACTION IN RNAI DRUGS

4.1.3. VENTURE FUNDING FOR RNAI DRUGS HAS INCREASED SUBSTANTIALLY

##### 4.2. PORTER'S FIVE FORCES ANALYSIS

4.2.1. BUYERS POWER

4.2.2. SUPPLIERS POWER

4.2.3. SUBSTITUTION

4.2.4. NEW ENTRANTS

4.2.5. INDUSTRY RIVALRY

##### 4.3. GROWTH PROSPECT MAPPING

4.3.1. GROWTH PROSPECT MAPPING FOR GERMANY

##### 4.4. MARKET MATURITY ANALYSIS

##### 4.5. MARKET CONCENTRATION ANALYSIS

##### 4.6. VALUE CHAIN ANALYSIS

4.6.1. PRIMARY ACTIVITIES

4.6.1.1. RESEARCH AND DEVELOPMENT (R&D)

4.6.1.2. MANUFACTURING

4.6.1.3. LOGISTICS AND DISTRIBUTION

4.6.1.4. MARKETING AND SALES

4.6.1.5. AFTER-SALES SERVICE

4.6.2. SUPPORT ACTIVITIES

4.6.2.1. PROCUREMENT

4.6.2.2. TECHNOLOGY DEVELOPMENT

4.6.2.3. HUMAN RESOURCE MANAGEMENT

4.6.2.4. FIRM INFRASTRUCTURE

4.6.2.5. REGULATORY AFFAIRS AND COMPLIANCE

##### 4.7. KEY BUYING CRITERIA

4.7.1. EFFICACY AND SAFETY

4.7.2. MECHANISM OF ACTION AND TARGET SPECIFICITY

4.7.3. DELIVERY SYSTEM AND ADMINISTRATION ROUTE

4.7.4. COMPETITIVE ADVANTAGE AND DIFFERENTIATION

4.7.5. REGULATORY APPROVAL AND COMPLIANCE

4.7.6. COST AND REIMBURSEMENT

4.7.7. INTELLECTUAL PROPERTY AND EXCLUSIVITY

4.7.8. MANUFACTURING CAPABILITIES AND SUPPLY CHAIN

4.7.9. COMPANY REPUTATION AND EXPERIENCE

#### 5. MARKET BY APPLICATION

##### 5.1. ONCOLOGY

5.1.1. MARKET FORECAST FIGURE

5.1.2. SEGMENT ANALYSIS

##### 5.2. INFECTIOUS DISEASE

5.2.1. MARKET FORECAST FIGURE

5.2.2. SEGMENT ANALYSIS

##### 5.3. NEUROLOGY

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.3.1. MARKET FORECAST FIGURE
- 5.3.2. SEGMENT ANALYSIS
- 5.4. CARDIOLOGY
  - 5.4.1. MARKET FORECAST FIGURE
  - 5.4.2. SEGMENT ANALYSIS
- 5.5. METABOLIC DISORDERS
  - 5.5.1. MARKET FORECAST FIGURE
  - 5.5.2. SEGMENT ANALYSIS
- 5.6. OPHTHALMOLOGY
  - 5.6.1. MARKET FORECAST FIGURE
  - 5.6.2. SEGMENT ANALYSIS
- 5.7. UROLOGY
  - 5.7.1. MARKET FORECAST FIGURE
  - 5.7.2. SEGMENT ANALYSIS
- 5.8. OTHER APPLICATIONS
  - 5.8.1. MARKET FORECAST FIGURE
  - 5.8.2. SEGMENT ANALYSIS
- 6. MARKET BY TECHNOLOGY
  - 6.1. NANOPARTICLE DRUG DELIVERY
    - 6.1.1. MARKET FORECAST FIGURE
    - 6.1.2. SEGMENT ANALYSIS
  - 6.2. PULMONARY DRUG DELIVERY
    - 6.2.1. MARKET FORECAST FIGURE
    - 6.2.2. SEGMENT ANALYSIS
  - 6.3. NUCLEIC ACID DRUG DELIVERY
    - 6.3.1. MARKET FORECAST FIGURE
    - 6.3.2. SEGMENT ANALYSIS
  - 6.4. APTAMER DRUG DELIVERY
    - 6.4.1. MARKET FORECAST FIGURE
    - 6.4.2. SEGMENT ANALYSIS
- 7. COMPETITIVE LANDSCAPE
  - 7.1. KEY MARKET STRATEGIES
    - 7.1.1. PRODUCT LAUNCHES & DEVELOPMENTS
    - 7.1.2. PARTNERSHIPS & AGREEMENTS
  - 7.2. COMPANY PROFILES
    - 7.2.1. ALNYLAM PHARMACEUTICALS INC
      - 7.2.1.1. COMPANY OVERVIEW
      - 7.2.1.2. PRODUCT PORTFOLIO
      - 7.2.1.3. STRENGTHS & CHALLENGES
    - 7.2.2. ARBUTUS BIOPHARMA CORP
      - 7.2.2.1. COMPANY OVERVIEW
      - 7.2.2.2. PRODUCT PORTFOLIO
      - 7.2.2.3. STRENGTHS & CHALLENGES
    - 7.2.3. ARCTURUS THERAPEUTICS INC
      - 7.2.3.1. COMPANY OVERVIEW
      - 7.2.3.2. PRODUCT PORTFOLIO
      - 7.2.3.3. STRENGTHS & CHALLENGES

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

#### 7.2.4. ARROWHEAD PHARMACEUTICALS INC

##### 7.2.4.1. COMPANY OVERVIEW

##### 7.2.4.2. PRODUCT PORTFOLIO

##### 7.2.4.3. STRENGTHS & CHALLENGES

#### 7.2.5. IONIS PHARMACEUTICALS INC

##### 7.2.5.1. COMPANY OVERVIEW

##### 7.2.5.2. PRODUCT PORTFOLIO

##### 7.2.5.3. STRENGTHS & CHALLENGES

#### 7.2.6. SILENCE THERAPEUTICS PLC

##### 7.2.6.1. COMPANY OVERVIEW

##### 7.2.6.2. PRODUCT PORTFOLIO

##### 7.2.6.3. STRENGTHS & CHALLENGES

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Germany Rna Interference (Rnai) Drug Delivery Market Forecast 2024-2032

Market Report | 2024-06-17 | 138 pages | Inkwood Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User Price	\$1100.00
	Global Site License	\$1500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com